Thrombomodulin deficiency in human diabetic nerve microvasculature

Diabetes

Volumn 51, Issue 6, 2002, Pages 1957-1963

  Hafer Macko, Charlene E ^a,b   Ivey, Frederick M ^a,b   Gyure, Kymberly A ^a   Sorkin, John D ^a,b   Macko, Richard F ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; THROMBOMODULIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; MICROVASCULATURE; NERVE BIOPSY; NEUROPATHOLOGY; NEUROPATHY; PATHOGENESIS; PRIORITY JOURNAL; SURAL NERVE;

EID: 0036267007     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.6.1957     Document Type: Article

References (40)

1. The prevalence by staged severity of types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study
2. Small vessel disease in progressive diabetic neuropathy associated with good metabolic control
3. Ultrastructural morphometric features of human sural nerve endoneurial microvessels
4. The protein C anticoagulant pathway
5. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V
6. Alteration of fibrin network by activated protein C
7. Resistance to activated protein C as a basis for venous thrombosis
8. Protein C activation following coronary artery occlusion in the in situ porcine heart
9. Prevention of arterial reocclusion after thrombolysis with activated protein C: Comparison with heparin in a canine model of coronary artery thrombosis
10. Efficacy and safety of recombinant human activated protein C for severe sepsis
11. Impairments of the protein C system and fibrinolysis in infection-associated stroke
12. Brain specific protein C activation during carotid artery occlusion in humans
13. Brain injury and cerebrovascular fibrin deposition correlate with reduced antithrombotic brain capillary functions in a hypertensive stroke model
14. Regional distribution of thrombomodulin in human brain
15. Thrombomodulin expression in bovine brain capillaries: Anticoagulant function of the blood-brain barrier, regional differences, and regulatory mechanisms
16. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties
17. Localization in human diabetic peripheral nerve of Nε-carboxymethyllysine-protein adducts, an advanced glycation endproduct
18. Relationship between soluble thrombomodulin in plasma and coagulation or fibrinolysis in type 2 diabetes
19. Plasma thrombomodulin: A marker for microvascular complications in diabetes mellitus
20. Models for longitudinal data: A generalized estimating equation approach
21. Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits
22. Mechanism of protein C-dependent clot lysis: Role of plasminogen activator inhibitor
23. Role of coagulation inhibitors in inflammation
24. Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke
25. Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model
26. Early loss of thrombomodulin expression impairs vein graft thrombo-resistance: Implications for vein graft failure
27. Protein C prevents coagulopathic and lethal effects of Escherichia coli injection in the baboon
28. Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system
29. Endothelium specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis
30. Characterization of a mouse model for thrombomodulin deficiency
31. Mechanisms of elevation of serum and urinary concentrations of soluble thrombomodulin in diabetic patients: Possible application as a marker for vascular endothelial injury
32. +)-ATPase activity and thrombomodulin expression in streptozotocin-induced diabetic rats
33. Interleukin-1 induces endothelial cell procoagulant while suppressing cell surface anticoagulant activity
34. Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: In vivo and in vitro studies
35. Reversal of experimental diabetic neuropathy by VEGF gene transfer
36. Thrombomodulin-dependent anticoagulant activity is regulated by vascular endothelial growth factor
37. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester
38. Expression of thrombomodulin in atherosclerotic lesions and mitogenic activity of recombinant thrombomodulin in vascular smooth muscle cells
39. Hypoxia modulates the barrier and coagulant function of cultured bovine endothelium: Increased monolayer permeability and induction of procoagulant properties